Lauffenburger Julie C, Landon Joan E, Fischer Michael A
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.
J Gen Intern Med. 2017 Jun;32(6):619-625. doi: 10.1007/s11606-016-3972-z. Epub 2017 Jan 3.
New trial evidence suggests that many patients may require more aggressive pharmacologic management to achieve lower blood pressure goals. Especially when first initiating anti-hypertensive treatment, it is unknown whether starting patients on multiple medications may be better for long-term adherence and persistence compared with starting one medication.
To examine contemporary patterns of anti-hypertensive therapy initiation and compare long-term adherence and persistence among patients initiating fixed-dose combinations and single anti-hypertensive therapies.
Retrospective cohort study.
Using claims from a large nationwide insurer, we identified all patients initiating oral hypertension treatment from 2009 to 2013. We categorized patients into three categories based on the number and type of anti-hypertensive medications they initiated: a fixed-dose combination, a multi-pill combination or a single therapy.
The primary outcome was persistence to any anti-hypertensive medication, either the initiated medication or other anti-hypertensive, 12 months after initiation in administrative claims. We also measured adherence to at least one anti-hypertensive in the 12 months after initiation and refilling at least one anti-hypertensive medication as outcomes. Full adherence was defined as having ≥80% of potential days covered with medication. Multivariable modified Poisson regression models were used to examine the association between initiating a fixed-dose combination anti-hypertensive and medication outcomes.
Of the 484,493 patients who initiated oral anti-hypertensives, 78,958 patients initiated fixed-dose combinations, 383,269 initiated a single therapy, and 22,266 initiated multi-pill combinations. Patients initiating fixed-dose combinations were 9% more likely to be persistent (relative risk [RR]: 1.09, 95% CI: 1.08-1.10) and 13% more likely to be adherent (RR: 1.13 95% CI: 1.11-1.14) than those who started on a single anti-hypertensive therapy. Refill rates were also slightly higher among fixed-dose combination initiators.
Fixed-dose combination pills appear to enhance adherence and persistence to anti-hypertensive medications among commercially insured patients starting treatment compared with single therapy.
新的试验证据表明,许多患者可能需要更积极的药物治疗管理以实现更低的血压目标。特别是在首次启动抗高血压治疗时,与开始使用一种药物相比,一开始就让患者使用多种药物是否对长期依从性和持续性更好尚不清楚。
研究当代抗高血压治疗启动模式,并比较开始使用固定剂量联合用药和单一抗高血压治疗的患者的长期依从性和持续性。
回顾性队列研究。
利用一家大型全国性保险公司的理赔数据,我们确定了2009年至2013年所有开始口服高血压治疗的患者。我们根据患者开始使用的抗高血压药物的数量和类型将其分为三类:固定剂量联合用药、多片联合用药或单一疗法。
主要结局是在行政理赔中开始治疗12个月后对任何抗高血压药物(开始使用的药物或其他抗高血压药物)的持续性。我们还将开始治疗后12个月内对至少一种抗高血压药物的依从性以及至少重新填充一次抗高血压药物作为结局进行测量。完全依从性定义为用药覆盖的潜在天数≥80%。使用多变量修正泊松回归模型来研究开始使用固定剂量联合抗高血压药物与药物治疗结局之间的关联。
在484493例开始口服抗高血压药物的患者中,78958例患者开始使用固定剂量联合用药,383269例开始单一疗法,22266例开始多片联合用药。与开始单一抗高血压治疗的患者相比,开始使用固定剂量联合用药的患者持续性高9%(相对风险[RR]:1.09,95%置信区间:1.08–1.10),依从性高13%(RR:1.13,95%置信区间:1.11–1.14)。固定剂量联合用药起始者的重新填充率也略高。
与单一疗法相比,固定剂量联合用药似乎能提高商业保险患者开始治疗时对抗高血压药物的依从性和持续性。